Logo
Banner

Manzamine A

Manzamine A

Catalog No.: PC0056

Size: 1 mg,5 mg, 10 mg, 500 mg


Description

Manzamine A is an orally active β-carboline alkaloid that specifically inhibits GSK-3β and CDK-5 with IC50 of 10.2 μM and 1.5 μM, respectively. Manzamine A targets vacuolar ATPase and inhibits autophagy in pancreatic cancer cells. Manzamine A has antimalarial and anticancer activity. Manzamine A also exhibits potent anti-HSV-1 activity.

Molecular Weight 548.76
Formula C36H44N4O
CAS No. 104196-68-1
SMILES O[C@]1(CC/C=C\CCCC2)[C@@]3([H])[C@@](C[C@@]4([H])N3CCCC/C=C\4)(C[N@@]2CC5)[C@]5([H])C(C6=C(NC7=CC=CC=C87)C8=CC=N6)=C1
Shipping Room temperature in continental US; may vary elsewhere.
Storage Please store the product under the recommended conditions in the Certificate of Analysis.
In Vitro Manzamine A (5-50 µM, 18 h) decreases tau phosphorylation, measured with ELISA.
Manzamine A (10 µM) inhibits yeast S. cerevisiae growth by 30%.
Manzamine A displays a few enlarged vacuoles in yeast.
Manzamine A (2.5-10 µM, 24 h) increases acidity in pancreatic cancer cells and non-malignant Vero cells.
Manzamine A (1 µM, 24 h) inhibits HSV-1 infection in SIRC cells.
Manzamine A shows antimalarial activity with an IC50 of 8.0 nM (D6 clone) and 11 nM (W2 clone).
In Vivo Manzamine A (50 and 100 mol/kg, p.o. or i.p.) inhibits the growth of the rodent malaria parasite Plasmodium berghei in infected mice.
Manzamine A (8 mg/kg, i.p., daily for 8 consecutive days) prolongs the survival of SW mice to 20 days.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.